Research Paper Volume 12, Issue 18 pp 18192—18208
MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression
Figure 3. Sorafenib treatment response of miR-216a-3p-overexpression and knock down HCC cells. (A) Representative colony formation images show crystal violet staining of DMSO or sorafenib-treated NC-, miR-216-3a OE-, and miR-216a-3p KD-Huh-7 cells. (B) MTT assay results show viability of DMSO or sorafenib-treated NC-, miR-216-3a OE-, and miR-216a-3p KD-Huh-7 cells. (C) Flow cytometry assay results show percentage apoptosis in DMSO or sorafenib-treated NC-, miR-216-3a OE-, and miR-216a-3p KD-Huh-7 cells. (D) Representative western blot images show cleaved-PARP1/caspase9/caspase3 levels in DMSO or sorafenib-treated NC-, miR-216-3a OE-, and miR-216a-3p KD-Huh-7 cells. (E) Representation colony formation images show crystal violet staining of DMSO or sorafenib-treated NC-, miR-216-3a OE-, and miR-216a-3p KD-HepG2 cells. (F) MTT assay results show viability of DMSO or sorafenib-treated NC-, miR-216-3a OE-, and miR-216a-3p KD-HepG2 cells. (G) Flow cytometry assay results show percentage apoptosis in DMSO or sorafenib-treated NC-, miR-216-3a OE-, and miR-216a-3p KD-HepG2 cells. (H) Representative western blot images show cleaved-PARP1/caspase9/caspase3 levels in DMSO or sorafenib-treated NC-, miR-216-3a OE-, and miR-216a-3p KD- HepG2 cells.